Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Phase I study of venetoclax/azacitidine or venetoclax in combination with ziftomenib KO-539 or standard induction cytarabine/daunorubicin 7+3 chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia
A FIH Phase I, Dose Escalation Study of SGR-2921 as Monotherapy in Subjects with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Study Type: Treatment
Phase: I
NCTID: NCT05961839
Principal Investigator:
Jesus Gonzalez Lugo
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Dociparstat Sodium in Combination with Standard Chemotherapy for the Treatment of Newly-Diagnosed Acute Myeloid Leukemia
A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients with Acute Myeloid Leukemia who are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation
Study Type: Treatment
Phase: I
NCTID: NCT04849910
Principal Investigator:
Muhammad Umair Mushtaq
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan GMI-1271 in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Phase IB/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination with Cytarabine and Daunorubicin in Patients Newly Diagnosed with Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
A Phase Ib/II Open-Label Study of APVO436 in Combination with Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia AML
Study Type: Treatment
Phase: I/II
NCTID: NCT06634394
Principal Investigator:
Tara Lin
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin 7+3 vs Daunorubicin and Cytarabine Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and Daunorubicin and Cytarabine Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk Adverse Acute Myeloid Leukemia as Determined by MYELOMATCH; A MYELOMATCH CLINICAL TRIAL
A PHASE 1 STUDY OF REVUMENIB, AZACITIDINE, AND VENETOCLAX AND IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA
Study Type: Treatment
Phase: I
NCTID: NCT06177067
Principal Investigator:
Keith August
An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation
Study Type: Treatment
Phase: Feasibility/Pilot
NCTID: NCT04203316
Principal Investigator:
Kevin Ginn